Patentability and Strategies for Novel Therapeutic Oligonucleotides
April 9, 2024 @ 13:00 – 15:00 CEST
Welcome to this seminar to learn more about intellectual properties regarding therapeutic oligonucleotides and strategies how to protect your invention. The seminar is organized by OligoNova Hub and SciLifeLab Drug Discovery and Development and is a hybrid event (Zoom or in-person at GoCo House).
- OligoNova Hub/ScilifeLab DDD: Pär Matsson, 5 min
- AstraZeneca: Peter Storm 20 min
- Ribocure: (TBC) 20 min
Patentability and Strategies for Therapeutic Oligonucleotides
- Potter Clarkson: Fiona Hey, Kevin Rich and Louise Tottie
Panel discussion questions
- Moderator: OligoNova Hub/DDD
Moderator: OligoNova Hub/DDD
Protecting your innovation and future proofing your enterprise may well mean the difference between commercial success and disappointment. However, it is not always obvious what IP you have, what you might be able to protect and what is worthwhile protecting. With a focus on oligonucleotide inventions, we will guide you through the requirements for patentability, highlighting the challenges associated with oligonucleotides and outlining an IP strategy that you can apply to help you to achieve your commercial goals.
For those that attend the seminar in person, there will be time to continue the discussion after the program with IP attorneys and academic and industrial scientist working with therapeutic oligonucleotides. Coffee and cake will be served.
OligoNova Hub offers industry-standard research and development capabilities to Swedish academic researchers, helping to transform their ideas into new oligonucleotide therapies. OligoNova Hub is part of the national SciLifeLab Drug Discovery and Development infrastructure, supporting academic researchers in drug discovery and development towards innovative commercial assets that will benefit patients.
Fredrik Wångsell, Research Advisor at OligoNova Hub/SciLifeLab Oligonucleotide Therapeutics Unit